Document:

Exhibit 10.78

 

SECOND
AMENDMENT TO LEASE

 

This Second Amendment to Lease (“Second
Amendment”) is made and entered into by and between Castro Mountain View, LLC, a California limited liability company, and CP6CC, LLC, a Delaware limited liability company,
as tenants in common and successor in interest (collectively, the “Landlord”)
and Vivus, Inc., a Delaware
corporation (“Tenant”).  This Second Amendment amends the Lease
(defined below) and is made and entered into effective as of November 12,
2009 (“Effective Date”).

 

RECITALS

 

A.            WHEREAS, Tenant and Landlord’s
predecessor in interest have entered into a certain Lease Agreement dated October 16,
2006 (“Original Lease”), as amended by a First Amendment to Lease dated November 18,
2008 (the “First Amendment”) (the Original Lease and the First Amendment
referred to herein collectively as the “Lease”), for approximately 14,237
square feet, located at 1172 Castro Street which is part of a two building
complex (“Complex”), in the City of Mountain View, County of Santa Clara, State
of California (the “Original Premises”); and

 

B.            WHEREAS, Tenant and Landlord now
desire to amend the terms of the Lease on the terms and conditions set forth
below.

 

AGREEMENT

 

NOW,
THEREFORE, in consideration of the covenants and agreements contained herein,
and for good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties do hereby agree as follows:

 

1.             Expansion Space:  Commencing on January 1, 2010 (“Expansion
Space Commencement Date”) and continuing through July 31, 2011 (“Expansion
Period”), the Leased Premises is hereby expanded to include Suite 210,
located in the 1174 Castro Street building, consisting of approximately 3,769
square feet (the “Expansion Space”).

 

2.             Base
Monthly Rent and Additional Rent:

 

a.             Original Premises. 
During the Expansion Period, Minimum Rent for the Original Premises,
Additional Rent for the Original Premises, and the total of Fixed Minimum Rent
and Additional Rent for the Original Premises shall continue to be payable by
Tenant to Landlord in those amounts as set forth in Section 2 and Section 3
of the First Amendment.  Tenant’s Expense
Share for the Original Premises shall be as set forth in Section 3 of the
First Amendment and shall not be changed by this Second Amendment.

 

b.             Expansion
Space.

 

i.              Expansion
Space Base Monthly Rent.  In
addition to the payment of Minimum Rent and Additional Rent on the Original
Premises as set forth in the First Amendment, during the Expansion Period,
Tenant shall pay to Landlord Base Monthly Rent 

 

1

 

(also
referred to in the Lease as “Minimum Rent” and “Fixed Minimum Rent”) for the
Expansion Space (“Expansion Space Base Monthly Rent”) on the first day of each
month in equal monthly installments without offset or deduction, as follows:

 

	
   

  	
  Period

  	
   

  	
  Expansion Space Base

  Monthly Rent

  (per rentable square foot)

  	
   

  	
  Expansion Space Base

  Monthly Rent

  (total per month)

  	
   

  
	
   

  	
  1/01/2010 through 7/31/2011

  	
   

  	
  $

  	
  2.25

  	
   

  	
  $

  	
  8,480.25

  	
   

  
									

 

In
addition to the payment of Expansion Space Base Monthly Rent, Tenant shall pay
Additional Rent on the Expansion Space as set forth in Section 2.b.ii of
this Second Amendment.

 

ii              Expansion
Space Additional Rent.  During
the Expansion Period, Tenant shall pay Additional Rent on the Expansion
Space.  Tenant’s Expense Share for the
Expansion Space shall mean the percentage obtained by dividing the rentable
square footage 3,769 of the Expansion Space at the time of calculation by the
rentable square footage of all buildings located on the property at the time of
calculation.  Such percentage is
currently 13.22% of the 1174 building and 8.82% of the Complex.   In the event that any portion of the Property
is sold by the Landlord, or the rentable square footage of the Expansion Space
or the Property is otherwise changed, Tenant’s Expense Share for the Expansion
Space shall be recalculated to equal the percentage described in the second
sentence of this paragraph, so that the aggregate Tenant’s Expense Share of all
tenants of the property shall equal 100%. 
Tenant’s Expense Share for the Expansion Space during the 2010 calendar
year is estimated to be one dollar and 34/100 ($1.34) per square foot, per
month.

 

4.             Expansion
Space As Is Condition: 
Landlord shall deliver the Expansion Space in an “as is” condition.  On or before the expiration of the Lease
Term, including any extension of the Lease Term, Tenant shall:  (i) vacate and surrender the Expansion
Space; (ii) remove all of Tenant’s personal property from the Expansion
Space; (iii) remove any tenant improvements, additions or changes made to
the interior of the Expansion Space by Tenant during the Lease Term; and (iv) repair
and/or restore, or cause to be repaired or restored, the Expansion Space and
every portion thereof to the same condition as existed prior to Tenant’s
acceptance of the Expansion Space.

 

5.             Delay of Expansion Space
Commencement Date:  Tenant is
aware and understands that the Expansion Space Commencement Date of January 1,
2010 is subject to Landlord gaining possession of the Expansion Space in a
timely manner from the current tenant in possession.  If for any reason whatsoever Landlord cannot
deliver possession of the Expansion Space by January 1, 2010, this Lease
will not be void or voidable, nor shall Landlord be liable to Tenant for any
loss or damage resulting therefrom. 
However, the Expansion Space Commencement Date shall be delayed until
possession of the Expansion Space is delivered to Tenant.  If Landlord is unable to deliver possession
of the Expansion Space to Tenant by May 1, 2010, then Tenant may terminate
this Second Amendment by giving written notice to Landlord no later than May 2,
2010, time being strictly of the essence, and the parties shall have no further
liability thereafter accruing under this Lease. 
Landlord agrees to use commercially reasonable efforts to deliver the
Expansion Space to Tenant at the earliest possible date as set forth in this
Second 

 

2

 

Amendment,
including, without limitation, refusing to renew the current tenant’s lease,
refusing to allow such tenant the right to retain possession of the Expansion
Space and undertaking any necessary eviction proceedings in a timely manner
should such tenant seek to hold possession of the Expansion Space beyond the
term of the lease.

 

6.             Option to Extend:  The option to extend contained in Section 7
of the First Amendment shall apply to the Leased Premises, as amended by this
Second Amendment to include the Expansion Space.

 

7.             HVAC:  Tenant is aware that the
1174 building heating and air conditioning is part of an energy efficient
system.  Heating and air conditioning is
available in the building Monday through Friday from 6:00 am to 6:00 pm. and on
Saturdays from 6:00 am to 5:00 pm.  There
is no heating and air conditioning available on Sundays.

 

8.             Confidentiality:  Tenant acknowledges that this Second
Amendment is confidential and that Landlord shall suffer irreparable damage if
the contents of this Second Amendment are discovered by the other tenants at
Castro Commons, or any other third parties. 
Therefore, Tenant agrees that neither Tenant nor Tenant’s employees,
agents, representatives or attorneys, shall disclose, release or discuss the
contents of this Second Amendment to or with any third party for any reason;
provided, however, Tenant is authorized to disclose the contents of this Second
Amendment to third parties as follows:  (a) to
comply with applicable law or regulations (including, without limitation, any
rule, regulation or policy statement of any national securities exchange,
market or automated quotation system on which any of the Tenant’s securities
are listed or quoted) and (b) in connection with the Tenant’s financing or
partnering activities.

 

9.             Miscellaneous:  All terms not specifically defined herein are
as defined in the Lease.  Except as
amended or modified by this Second Amendment, all terms and conditions of the
Lease shall remain unchanged and in full force and effect and Landlord and
Tenant shall be bound thereby.  This
Second Amendment may be executed in one or more counterparts, which
counterparts shall together constitute an original document.

 

IN WITNESS WHEREOF, Landlord and Tenant have
caused this Second Amendment to be executed and made effective as of the Effective
Date.

 

	
  Tenant:

  	
   

  
	
   

  	
   

  
	
  VIVUS, Inc., a Delaware corporation

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ Timothy E. Morris

  	
   

  	
   

  
	
   

  	
   

  
	
  Title: VP Finance and Chief Financial Officer

  	
   

  
	
   

  	
   

  
	
  Date Executed: 11/16/09

  	
   

  
				

 

3

 

[Signatures continue on following page]

 

4

 

Landlord:

 

	
  Castro Mountain View, LLC, a California limited
  liability company

  
	
  By:

  	
  West Valley Properties, Inc.,

  	
   

  
	
   

  	
  a California corporation, Manager

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Jonathan Rayden

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Title:

  	
  President

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Date
  Executed: 11/17/09

  	
   

  
	
   

  	
   

  	
   

  
	
  By:

  	
  Guardian
  Equity Growth, Inc.,

  	
   

  
	
   

  	
  a
  California corporation, Manager

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/
  William Moison

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Title:

  	
  Partner

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Date
  Executed: 11/17/09

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  CP6CC, LLC, a Delaware limited liability company

  
	
  By:

  	
  Cupertino
  Partners VI, a California limited partnership, its Sole Member

  
	
  By:

  	
  West
  Valley Properties, Inc., a California corporation, its General Partner

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Jonathan Rayden

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Title:

  	
  President

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Date
  Executed: 11/17/09

  	
   

  
					

 

5Exhibit 10.79

 

ASSIGNMENT AGREEMENT

 

This Assignment Agreement
(the “Agreement”) is made this 16th day of October, 2001 (the Effective
Date”), by and between Thomas Najarian, M.D., an individual with a principal place of business at
2280 Sunset Drive, Suite D, Osos, CA 93402 (“Assignor”), and VIVUS, Inc., a company incorporated under the laws of
Delaware, having its principal place of business at 1172 Castro Street,
Mountain View, California 94040 (“Assignee”), collectively, the “Parties.”

 

Whereas, Assignor is the owner of that certain
Invention as defined below; and

 

Whereas, Assignee is desirous of acquiring all
title, right, interest, benefits and privileges to the Invention, all inventive
subject matter, and all materials embodying the certain invention;

 

Now,
therefore, for
valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties hereby agree and act as follows:

 

1.                                       For purposes of this Agreement, “Invention”
means a novel therapy for treating obesity and other disorders, comprising
treating a subject with a therapeutically effective amount of a combination of
a sympathomimetic agent and an anticonvulsant agent, including, without
limitation, those inventions described and/or embodied in the following: all
notes, records, data, reports, and the “Patent Applications”, attached
hereto as Exhibit 1, related to the combined use of a
sympathomimetic agent and an anticonvulsant agent for the treatment of obesity
and other disorders.

 

2.                                       Assignor hereby, irrevocably and without
reservation:

 

2.1                                 Assigns, sells, transfers and conveys to
Assignee all right, title and interest in and to:

 

(i)                                     the Invention;

 

(ii)                                  any U.S. patent applications filed that
disclose or claim the Invention, including the U.S. Patent Applications, any
divisional, continuation and continuation-in-part applications thereof, any new
U.S patent applications related thereto, and any U.S. patents issuing on the
foregoing applications, including reissued and re-examined versions thereof;

 

(iii)                               any non-U.S. patent applications filed
that disclose or claim the Invention, including the non-U.S. Patent
Applications, divisional and other later-filed non-U.S. applications, whether
or not claiming priority or otherwise related to the U.S. patent applications
referenced in (ii) above; and any non-U.S. patents issuing on the
foregoing non-U.S. patent applications.

 

2.2                                 Assignee shall have the right, but not
the obligation, either on its own or through a third party (a “Licensee”)
to commercially exploit the Invention embodied within the Patent Rights,
including without limitation the development and commericialization of Products
within the Patent Rights.  “Patent
Rights” shall mean any U.S. or foreign patents issued or pending pursuant
to Sections 2.1 (ii) and (iii) above.  In the event that Assignee decides in its
sole discretion not to commercially exploit the Invention embodied within the
Patent Rights, Assignee agrees to 

 

 

take all
reasonable steps necessary to assign its rights to the Invention back to
Assignor, including all patents and patent applications within the Patent
Rights.  In such event, this Agreement
shall terminate as of the date of such decision, and Assignee shall have no
further obligations to Assignor except as set forth in this Section 2.2.

 

2.3                                 Assignor hereby warrants and represents
that (i) it has not entered into and will not enter into any assignment,
contract or understanding in conflict herewith, (ii) the Patent
Applications include all patents and pending patent applications related to the
Invention, and (iii) that there are no threatened or pending actions,
lawsuits, claims or arbitration proceedings in any way relating to the
Invention, such patents and patent applications.  Assignor agrees that Assignee has provided to
Assignor full consideration for the assignment made herein.

 

2.4                                 The terms and covenants of this Agreement
shall inure to the benefit of Assignee, its successors, assigns and other legal
representatives, and shall be binding upon Assignor, his heirs, legal
representatives and assigns.

 

3.                                       Assignee agrees to pay Assignor, upon the
specified event below, the following non refundable payments:

 

3.1                                 Twenty Thousand United States
Dollars ($20,000.00) and 10,000 options to purchase VIVUS Common Stock
pursuant to Assignee’s 1991 Incentive Stock Plan or any successor plan thereto
(the “Stock Plan”), attached hereto as Exhibit 2, and in the
form of the Stock Option Agreement (the “Stock Agreement”), attached
hereto as Exhibit 3, upon execution of this Agreement.

 

3.2                                 Fifty Thousand United States
Dollars ($50,000.00) and 10,000 options to purchase VIVUS Common Stock
pursuant to the Stock Plan, and in the form of the Stock Agreement upon the
issuance of a U.S. patent (“Issued U.S. Patent”) by the United States
Patent and Trademark Office (“USPTO”) deriving from or claiming priority
to any of the U.S. Patent Applications with claims that are substantially the
same as those claims included in the Patent Applications, and the occurrence of
at least one of the following events:

 

(i)                                     Any and all U.S. patent applications
claiming priority to International Application No. PCT/US00/04187, filed February 18,
2000, listing the inventor as Susan McElroy (the “McElroy Applications”),
are either (i) issued by the USPTO with no claims that interfere, overlap
or otherwise conflict with the claims in the Issued U.S. Patent above and/or
affect Assignee’s freedom to operate with respect to the Invention, or (ii) abandoned.

 

(ii)                                  Assignor provides Assignee with evidence
that demonstrates to Assignee’s satisfaction that Assignor was the original and
first inventor of the subject matter claimed in the Issued U.S. Patent above,
thereby providing priority to such patent in the USPTO over any other patents
or patent applications in the U.S. claiming the subject matter, including the
McElroy Applications.

 

2

 

3.3                                 One Hundred Fifty Thousand United States
Dollars ($150,000.00) and 20,000 options to purchase VIVUS Common Stock
pursuant the Stock Plan, and in the form of the Stock Agreement, upon the
completion of a well-controlled clinical study designed and performed by
Assignee or a Licensee that demonstrates in a statistically significant manner
that the combination of the sympathomimetic agent and the anticonvulsant agent
tested in such study has (i) greater efficacy and similar safety than
either treatment alone, or (ii) similar efficacy and greater safety than
either treatment alone; and

 

3.4                                 One Million United States
Dollars ($1,000,000.00) and 20,000 options to purchase VIVUS Common Stock
pursuant to the Stock Plan, and in the form of the Stock Agreement, upon the
receipt of marketing approval by Assignee or a Licensee for a Product (as
defined below) in the United States by the Food and Drug Administration.

 

4.                                       In addition, Assignee agrees to pay
Assignor the following royalties on annual Net Sales of Products as follows:

 

4.1                                 *** percent (***%) of Net Sales up
to $300 million U.S. dollars;

 

4.2                                 *** percent (***%) of Net Sales
greater than $300 million up to $600 million U.S. dollars;

 

4.3                                 *** percent (***%) of Net Sales
greater than $600 million up to $900 million U.S. dollars; and

 

4.4                                 *** percent (***%) of Net Sales
greater than $900 million U.S. dollars.

 

“Net Sales” shall
mean the net revenue received by Assignee on worldwide sales of a Product
calculated in accordance with Generally Acceptable Accounting Principles in the
United States consistently applied.

 

“Product” shall
mean an approved pharmaceutical product utilizing a combination of a
sympathomimetic agent and an anticonvulsant agent for the treatment of obesity,
the sale of which would infringe upon a Valid Claim.

 

“Valid Claim”
shall mean on a country-by-country basis (i) a claim of an issued and
unexpired patent within the Patent Rights, which has not been held
unenforceable or invalid by a court or other governmental agency of competent
jurisdiction, and which has not been disclaimed or admitted to be invalid or
unenforceable through reissue or otherwise; or (ii) a claim of a pending
patent application within the Patent Rights.

 

5.                                       Notwithstanding the provisions of Article 4
above, if by reason of Assignor’s action or failure to act causes Assignee to
not be the exclusive assignee of any portion of the Invention, then the
royalties to be paid to Assignor by Assignee shall be reduced to zero
percent (0.0%) of Net Sales of Products.

 

*** Certain information has been omitted and filed separately with the
Commission.  Confidential treatment has
been requested with respect to the omitted portions.

 

3

 

6.                                       The remittance of royalties payable on
Net Sales of Product will be payable to Assignor or his heir apparent in United
States Dollars. Any tax required to be withheld by Assignee or any affiliate of
Assignee under the laws of any country for the account of Assignor shall be
promptly paid by Assignee or said affiliate for and on behalf of Assignor to
the appropriate governmental authority. 
Assignee or said affiliate shall furnish Assignor with proof of payment
of such tax together with official or other appropriate evidence issued by the
appropriate governmental authority to enable Assignor to support a claim for
income tax credit in respect of any sum so withheld.  Any such tax required to be withheld shall be
an expense of and borne solely by Assignor.

 

7.                                       Assignee shall keep complete and accurate
records of Net Sales of Product with respect to which a royalty is payable by
Assignee according to this Agreement. 
Within sixty (60) days following each quarterly period of a
calendar year after the date on which royalties are due under this Agreement,
Assignee shall render to Assignor a written report setting forth the Net Sales
of Products and the royalty due and payable. 
Assignee shall, upon rendering such report, remit to Assignor the amount
of royalty shown thereby to be due.

 

8.                                       If a patent or patents of a third party
in any country should exist during the term of Assignee’s obligation to pay
royalties pursuant to Section 4 of this Agreement covering the manufacture,
use or sale of a Product, and if it should prove in Assignee’s reasonable
judgment impractical or impossible for Assignee or any affiliate or licensor of
Assignee to continue the activity or activities assigned hereunder without
obtaining a royalty-bearing license from such third party under such patent or
patents in said country, then Assignee shall be entitled to a credit against
the payments due hereunder of an amount equal to the royalty paid to such third
party, not to exceed fifty percent (50%) of the royalty payment due under Section 4
of this Agreement, arising from the manufacture, use, or sale of Product in
said country.

 

9.                                       If at any time and from time to time a
third party in any country shall, under the right of a compulsory license granted
or ordered to be granted by a competent governmental authority, manufacture or
use or sell any Product with respect to which royalties shall be payable
pursuant to Article 4 above, then Assignee shall be entitled to reduce its
royalty obligation in such country to an amount equal to the royalty paid by
such third party under such compulsory license. 
In the event that Assignee reduces the royalty on Net Sales due to such
compulsory licenses, then the Assignee shall provide copies of all such
compulsory licenses to Assignor.

 

10.                                 The obligation to pay royalties to
Assignor pursuant to Article 4 will terminate on a country-by-country
basis upon the expiration of the last to expire Valid Claim with respect to
such country.  Assignee’s obligation to
pay royalties pursuant to Section 4 above is imposed only once with
respect to each unit of Product sold.  No
more than one payment shall be due with respect to the sale of a particular
Product.

 

11.                                 In the event that Assignee assigns,
licenses or sells the Patent Rights to a third party in a transaction that
includes cash payments paid by such third party to Assignee and does not
include any obligation for such third party to pay royalties to Assignee for
Product sales, then 

 

4

 

Assignee shall pay
to Assignor an amount equal to five percent (5%) of such cash payments
received from such third party.

 

12.                                 Assignor agrees to assist Assignee, or
its designee, at the Assignee’s expense, in every proper way to secure or enforce
the Assignee’s rights in the Invention and any patents, or other intellectual
property rights relating thereto in any and all countries, including the
disclosure to the Assignee of all pertinent information and data with respect
thereto, the execution of all applications, specifications, oaths, assignments
and all other instruments which the Assignee shall deem necessary in order to
apply for and obtain such rights and in order to assign and convey to the
Assignee, its successors, assigns and nominees the sole and exclusive rights,
title and interest in and to such Inventions and any patents, or other
intellectual property rights relating thereto.

 

13.                                 This Agreement shall be governed by the
laws of the State of Delaware, without reference to conflict of laws
principles.  The parties to this
Agreement expressly agree to submit to the jurisdiction and venue of either the
Federal or state courts in Santa Clara County, California, as appropriate, as
to any legal action brought to enforce, interpret or receive damages for breach
of this Agreement and further agree that any such action shall be filed with
said court.  This document contains the
entire Agreement between the parties with respect to the subject matter hereof.  Any failure to enforce any provision of the
Agreement shall not constitute a waiver thereof or of any other provision.  This Agreement may not be amended, nor any
obligation waived, except by a writing signed by both parties.  If any provision of this Agreement is held by
a court of competent jurisdiction to be unenforceable, then such provision
shall be eliminated or limited to the extent required by applicable law and
this Agreement, as so modified, shall remain enforceable in accordance with its
terms.

 

14.                                 Except as required by law, neither party
shall make any public announcement, statement, response to questions or other
disclosure concerning this Agreement nor the terms nor the subject matter
hereof without the prior written consent of the other party.

 

15.                                 This Agreement has been prepared jointly
and shall NOT be strictly construed against neither party.

 

16.                                 This Agreement may be executed in two or
more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

 

IN
WITNESS WHEREOF,
each of the parties has caused this Agreement to be executed in the manner
appropriate to each, to be effective on the date first given above.

 

	
  VIVUS, Inc.,
  Assignee

  	
  Thomas
  Najarian, M.D., Assignor

  
	
   

  	
   

  
	
  By:

  	
  /s/ Leland F.
  Wilson

  	
   

  	
  By:

  	
  /s/ Thomas
  Najarian, M.D.

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
  President & CEO

  	
   

  	
  Title:

  	
  M.D.

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Date:

  	
  10/18/01

  	
   

  	
  Date:

  	
  10/16/01

  

 

5

 

EXHIBIT 1

 

Patent Applications

 

·                                          U.S. Serial No. 60/139,022 filed
with the United States Patent & Trademark Office on June 14, 1999
as a provisional application for “Combination Therapy for
Effecting Weight Loss and Treating Obesity” (expired), by inventor
Thomas Najarian.

 

·                                          U.S. Serial No. 60/178,563 filed
with the United States Patent & Trademark Office on January 26,
2000 as a provisional application “Combination Therapy for
Effecting Weight Loss and Treating Obesity” (expired), by inventor
Thomas Najarian.

 

·                                          U.S. Serial No. 60/181,265 filed
with the United States Patent & Trademark Office on February 9,
2000 as a provisional application “Combination Therapy for
Effecting Weight Loss and Treating Obesity” (expired), by inventor
Thomas Najarian.

 

·                                          U.S. Serial No. 09/593,555 filed with
the United States Patent & Trademark Office on June 14, 2000 as a
utility application “Combination Therapy for
Effecting Weight Loss and Treating Obesity” (pending), by inventor
Thomas Najarian, claiming priority to the provisional applications shown above
(U.S. Serial No. 60/139,022, U.S. Serial No. 60/178,563 and U.S.
Serial No. 60/181,265).

 

·                                          PCT Application No. PCT/US00/16434,
filed on June 14, 2000, entitled “Combination Therapy for
Effecting Weight Loss and Treating Obesity” (pending), published
under International Publication No. WO 00/76493 on December 21, 2000
and claiming priority to the provisional applications shown above (U.S. Serial No. 60/139,022,
U.S. Serial No. 60/178,563 and U.S. Serial No. 60/181,265).

 

1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]